Fong Clow
Corporate Officer/Principal at SUMMIT THERAPEUTICS INC.
Profile
Dr. Fong W.
Clow is a Chief Biometrics Officer at Summit Therapeutics, Inc. Dr. Clow was previously employed as a VP-Biostatistics Programming & Data Management by Pharmacyclics LLC, a Senior Vice President-Drug Development by Novacea, Inc., and a Head-Oncology Statistics by AbbVie, Inc. She received her undergraduate degree from Wuhan University, a graduate degree from Harvard T.H.
Chan School of Public Health and a doctorate degree from Harvard T.H.
Chan School of Public Health.
Fong Clow active positions
| Companies | Position | Start |
|---|---|---|
| SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 2023-10-15 |
Former positions of Fong Clow
| Companies | Position | End |
|---|---|---|
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Corporate Officer/Principal | 2009-02-02 |
| ABBVIE INC. | Corporate Officer/Principal | - |
| PHARMACYCLICS, INC. | Corporate Officer/Principal | - |
Training of Fong Clow
| Wuhan University | Undergraduate Degree |
| Harvard T.H. Chan School of Public Health | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SUMMIT THERAPEUTICS INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| Private companies | 2 |
|---|---|
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
- Stock Market
- Insiders
- Fong Clow
